Overview

Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL

Status:
RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of the Pro-Pola Pomalidomide, rituximab, orelabrutinib and polatuzumab vedotin) regimen in elderly patients (aged 70 years) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Phase:
NA
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University